Clinical Trials Browser

Phase 2 × Recurrence × Nivolumab × Clear all

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Phase 2 Completed

20 enrolled 13 charts

Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03557359 2025-11-03

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Phase 2 Completed

35 enrolled 9 charts

CNS

Glioma, Recurrence

NCT06931613 2025-04-17

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Phase 2 Enrolling by invitation

20 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT05476796 2024-10-24

LOGICAN

Phase 2 Recruiting

118 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT03620123 2022-11-18

OPTIM

Phase 2 Completed

54 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT04913922 2022-11-08

AARON

Phase 2 Unknown

30 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03132038 2022-01-11

NISCAHN

Phase 2 Completed

98 enrolled

Head & Neck

Neoplasm Metastasis, Recurrence, Salivary Gland Neoplasms

NCT02962804 2018-03-05

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

Phase 2 Withdrawn

Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Recurrence

Clinical Trials

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

LOGICAN

OPTIM

AARON

NISCAHN

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)